(1) To compare the efficacy and safety of a 14-day bismuth-amoxicillin-vonoprazan triple therapy versus a 14-day bismuth-based quadruple therapy as first-line treatments for H. pylori infection, and (2) To investigate the influence of H. pylori antibiotic resistance, along with host CYP3A4, CYP2C19, and IL-1B -511 genotypes, on the eradication efficacy of H. pylori therapies.
Subjects with Helicobacter pylori infection
Subjects with known hypersensitivity to the study drug.
Subjects with a history of gastric surgery.
Subjects with severe liver cirrhosis or uremia.
Subjects with a history of malignancy within the past five years.
Kaohsiung Medical University
Lead sponsor
Kaohsiung Veterans General Hospital.
Collaborator